Detalhe da pesquisa
1.
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
N Engl J Med
; 389(4): 335-347, 2023 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272512
2.
ctDNA improves prognostic prediction in relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.
Blood
; 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38427753
3.
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.
Ann Hematol
; 103(2): 475-488, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37695378
4.
Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma.
Acta Haematol
; : 1-6, 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38657575
5.
Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3.
Jpn J Clin Oncol
; 2024 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38794892
6.
Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment.
Ann Hematol
; 102(6): 1477-1483, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37115297
7.
Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies.
Ann Hematol
; 102(12): 3489-3497, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37668787
8.
[A retrospective analysis of 124 patients with multiple myeloma who received up-front autologous hematopoietic cell transplantation following triplet induction therapy].
Rinsho Ketsueki
; 64(11): 1397-1403, 2023.
Artigo
em Japonês
| MEDLINE | ID: mdl-38072424
9.
[Acute myeloid leukemia with t (8;21) translocation diagnosed at 21 weeks of gestation resulting in full-term delivery without chemotherapy].
Rinsho Ketsueki
; 64(8): 731-734, 2023.
Artigo
em Japonês
| MEDLINE | ID: mdl-37673623
10.
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
Cancer Sci
; 113(12): 4267-4276, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36052883
11.
Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan.
Future Oncol
; 2022 Nov 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36331578
12.
[Future therapeutic strategies for multiple myeloma].
Rinsho Ketsueki
; 63(6): 635-645, 2022.
Artigo
em Japonês
| MEDLINE | ID: mdl-35831199
13.
Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.
Ann Hematol
; 100(12): 2989-2995, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34430990
14.
Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse.
Int J Clin Oncol
; 26(11): 2142-2150, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34259983
15.
Spinal Cord Infarction in a Patient with Immune Thrombocytopenic Purpura.
J Stroke Cerebrovasc Dis
; 30(4): 105637, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33508727
16.
Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study.
Cancer Sci
; 111(9): 3367-3378, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32619037
17.
Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.
Ann Hematol
; 99(5): 1063-1072, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32248251
18.
The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Eur J Haematol
; 104(2): 110-115, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31733155
19.
[Antibody therapy for multiple myeloma: novel approaches and future perspectives].
Rinsho Ketsueki
; 61(8): 912-921, 2020.
Artigo
em Japonês
| MEDLINE | ID: mdl-32908055
20.
[Cost-effectiveness of peripheral blood stem cell collection using plerixafor: a single-center study].
Rinsho Ketsueki
; 61(11): 1563-1569, 2020.
Artigo
em Japonês
| MEDLINE | ID: mdl-33298647